ROLE OF GLYCATED ALBUMIN AS PREDICTOR OF GLYCEMIC STATUS IN END STAGE RENAL DISEASE IN COMPARISON TO GLYCATED HEMOGLOBIN.

Dialysis patients with diabetes and end-stage renal disease (ESRD) had lower levels of glycated hemoglobin than predicted, making it more difficult to accurately predict their diabetic condition. Glycated albumin (GA) is an intriguing marker for assessing diabetic status in these patients. In our study, we checked either GA is as accurate or better in predicting blood glucose control compared to glycated hemoglobin, in patients with or without ESRD. Case control study, involved three groups; 47 ESRD (without DM), 46 diabetic patients (without ESRD), 43 patients with DM and ESRD (with dialysis). Serum hemoglobin (Hb), fasting blood sugar (FBS), serum albumin (Alb), GA and HbA1c were measured. The HbA1c was significantly lower in DM patients with ESRD compared to DM patients without ESRD (8.14 ± 1.09% vs 9.18 ± 1.12%, p-value < 0.001) and both were significantly higher than those with ESRD and without DM (4.70 ± 0.39%). GA was not statistically significant in patients with DM with ESRD compared to DM patients without ESRD (3.52 ± 0.90% vs. 3.79 ± 0.94%, p-value = 0.231) and both were significantly higher than those with ESRD and without DM (1.32 ± 0.41%). In conclusion, Glycated albumin offered better prediction of blood glucose control than glycated hemoglobin in patients with ESRD. [ABSTRACT FROM AUTHOR]